

## Literatuur

1. Richtlijn voor behandeling van patiënten met trombotische microangiopathie. Nederlandse Vereniging voor Hematologie, maart 2021.
2. Kater AP, Van der Lelie J, Levi M. Trombotische microangiopathie: trombocytopenie en hemolytische anemie. *Ned Tijdschr Geneeskd* 2002; 146: 2343-47.
3. Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. *Blood Adv* 2017; 1(10): 590-600.
4. Alwan F, Mahdi D, Tayabali S, et al. Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura. *Br J Haematol* 2020; 191(5): 868-74.
5. George JN. How I treat patients with thrombotic thrombocytopenic purpura. *Blood* 2010; 116(20): 4060-69.
6. Moake J. Thrombotic microangiopathies. *N Engl J Med* 2002; 347: 589-600.
7. Routh JK, Koenig SC. Severe vitamin B12 deficiency mimicking thrombotic thrombocytopenic purpura. *Blood* 2014; 124(11): 1844.
8. Hematologiewijzer behandelprotocol 'Trombotische trombocytopenische purpura (TTP)'. [www.hematologie-wijzer.nl/home/behandelprotocollen/ttp](http://www.hematologie-wijzer.nl/home/behandelprotocollen/ttp).
9. Haque W, Alvarenga M, Vuppula S, et al. Retrospective analysis of bleeding events after central venous catheter placement in thrombotic thrombocytopenic purpura. *Transfus Apher Sci* 2021; 60(3): 103120.
10. Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. *Blood* 2015; 125(9): 1470-76.
11. Aanvraagprocedure Therapeutische Aferese Sanquin. Beschikbaar via: [www.sanquin.org/nl/producten-en-diensten/transfusiegeneskunde/afereze/index](http://www.sanquin.org/nl/producten-en-diensten/transfusiegeneskunde/afereze/index).
12. Wollersheim J, Fijnheer, R. Verwijdering van 'ultra large' von willebrandfactor door plasmaferese met filtratie- en centrifugatietechniek bij patiënten met trombotische trombocytopenische purpura. *Tijdschr Bloedtransfusie* 2009; (2): 93-99.
13. Brunskill SJ, Tusold A, Benjamin S, et al. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. *Transfus Med* 2007; 17(1): 17-35.
14. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. *N Engl J Med* 2019; 380(4): 335-46.
15. Vademecum Therapeutische Aferese, Sanquin Aferese Werkgroep (SAWG), versie 2020.
16. Peyvandi F, Scully M, Kremer Hovinga JA. Caplacizumab for acquired thrombotic thrombocytopenic purpura. *N Engl J Med* 2016; 374: 511-22.
17. Goshua G, Sinha P, Hendrickson JE, et al. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. *Blood* 2021; 137(7): 969-76.